Mirum Pharmaceuticals announced that the company will Travere Therapeutics’ bile acid product portfolio, including Cholbam® (cholic acid) and Chenodal® (chenodiol).
Under the agreement, Mirum will purchase Travere’s bile acid product portfolio for $445M, consisting of $210M upfront and $235M in potential sales-based milestone payments. Mirum will acquire Travere’s rights to Cholbam®, indicated for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease, and Chenodal®, indicated for the treatment of radiolucent stones in the gallbladder, which is also under Phase 3 clinical evaluation for cerebrotendinous xanthomatosis (CTX).